Background. Recent clinical trial data indicate that the use of angiotensin converting enzyme (ACE) inhibitors among patients with left ventricular dysfunction results in reduced rates of coronary thrombosis, a provocative finding that suggests a potential interaction between the renin-angiotensin system and fibrinolytic function.
P lasminogen activator inhibitor-1 (PAI-1) is the most important physiological inhibitor of tissuetype plasminogen activator (t-PA) in plasma,1'2 and elevated levels have been implicated in the pathogenesis of thromboembolic disease.3 Although the regulation of PAI-1 in vitro has been extensively studied,4-13 factors that control the production and secretion of PAI-1 in vivo are less well characterized.
Recently reported clinical trial data indicate that the administration of angiotensin converting enzyme (ACE) inhibitors to patients with left ventricular dysfunction following myocardial infarction results in reduced rates of recurrent coronary thrombosis,14,15 an observation that raises the possibility that angiotensin II (Ang II) may be involved directly in the thrombotic process. This observation is particularly intriguing as in vitro data indicate that Ang II selectively induces the production and secretion of PAI-1 in cultured astrocytes16 and endothelial cells17 and by the fact that elevated levels of PAI-1 appear to constitute a marker of risk for recurrent coronary thromboSiS. 18, 19 Furthermore, prospective clinical data suggest that individuals with high renin essential hypertension are at a fivefold greater risk of sustaining myocardial infarction than individuals with low renin essential hypertension,20 although the mechanisms underlying this excess risk are unclear. Based on these observations, we hypothesized that in vivo infusion of Ang II might effect changes in circulating levels of PAI-1 in humans.
Methods

Subjects
Ten volunteers, four normotensive subjects and six patients with essential hypertension, were studied in the Clinical Research Center of the Brigham and Women's Hospital. All subjects were maintained on a low-salt diet containing 10 mmol Na and 100 mmol K for at least 5 days to achieve external sodium balance. Protocols for participation were 
Laboratory Analyses
All blood samples were placed on ice and immediately centrifuged. The separated plasma was frozen and stored at -70°C until the time of assay. Plasma samples were assayed for t-PA antigen and PAI-1 antigen using a two-site enzyme-linked immunosorbent assay (kits purchased from Biopool AB, Umea, Sweden). Assays were performed in accordance with the manufacturer's instructions following a procedure described by Ranby et al. 21 Briefly, plasma samples were incubated in microtiter plates coated with monoclonal antibodies against the desired antigen, unbound antigens were washed off, and bound antigen was detected by addition peroxidase. Standard curves were constructed using dilutions of purified antigen in plasma. 
Statistical Analyses
Mean values for measured parameters were calculated at the start and end of each infusion, and the significance of any differences before and after infusion was determined using the paired Student's t test. In study 1, which assessed the dose-response effect of infusions on t-PA and PAI-1 antigens, a repeatedmeasures ANOVA was used to determine the significance of any difference between subjects receiving Ang II and subjects receiving 5% dextrose. All reported p values are two tailed.
Results
For all subjects receiving Ang II infusions, PAI-1 antigen levels increased from a mean of 20.1 ng/mL at baseline to 36.0 ng/mL at the end of the infusion period (p=0.008), whereas no significant change was observed among control subjects receiving 5% dextrose solution. In contrast, the t-PA antigen response to Ang II was heterogenous with seven subjects demonstrating a decrease, two demonstrating no change, and one demonstrating an increase. Overall, mean t-PA antigen levels decreased from 7.9 ng/mL at baseline to 4.6 ng/mL at the end of Ang II infusion, which is a decrease of borderline statistical significance (p=0.06). The Figure 2 illustrates the effects of Ang II infusion on the six hypertensive subjects enrolled in study 2 compared with the effects of 5% dextrose infusion on the normotensive controls. For the hypertensive subjects, mean PAM-i antigen levels increased from 23.7 to 37.7 ng/mL at the end of the 3.0-ng kg`-min`Ang II infusion, whereas mean PAI-1 levels decreased from 16.9 to 10.8 ng/mL in the control subjects receiving 5% dextrose solution (p=0.04). With regard to t-PA, no significant differences were found between Ang IIinfused subjects and subjects infused with 5% dextrose solution. Again, Ang II Taken together, these findings raise the possibility that Ang II may contribute to the development of a prothrombotic state at least in part by increasing plasma levels of PAT-1, thereby reducing the net activity of the endogenous fibrinolytic system. This potential relation between the renin-angiotensin system and fibrinolytic function may have important clinical and therapeutic consequences. Recently, two large-scale clinical trials have demonstrated that the administration of ACE inhibitors to patients with left ventricular dysfunction reduces the incidence of recurrent myocardial infarction by approximately 25%.14, 15 The mechanism of this newly recognized effect of ACE inhibition is, however, unknown. For example, among the protean actions of ACE inhibitors are their ability to regulate bradykinin,25 which can increase the production of prostacyclin, endotheliumderived relaxing factor, and t-PA. If, as our data suggest, Ang II also effects a direct increase in PAI-1, then a further action of ACE inhibition may be to improve endogenous fibrinolytic function among patients at high risk for recurrent ischemic events. Such a potential relation between the renin-angiotensin system and endogenous fibrinolytic function may also help to explain the observation that patients with high renin essential hypertension (who presumably also have high Ang II levels) appear to be at greater risk for coronary thrombosis than do patients with similar levels of hypertension but lower plasma renin activity. 20 Although the current data represent the first in vivo demonstration that Ang II affects circulating PAI-1
antigen levels, in vitro research from our laboratory indicates that Ang II induces the synthesis of PAI-1 in a dose-dependent fashion in cultured endothelial cells,17 a finding consistent with the recent report that Ang IT selectively stimulates the production of PAI-1 in cultured murine astrocytes.'6 Thus, these data strongly suggest that Ang II be added to the list of agents known to enhance endothelial PAI-1 synthesis and secretion, factors that include endotoxin,4-6 interleukin 1,7 tumor necrosis factor,8,9 transforming growth factor-.,9 insulin and insulinlike growth factors,10-'2 and the glucocorticoid hormones.13 In addition, because no pressor effects are generated in cell culture preparations, these in vitro findings from disparate cell sources make it highly unlikely that the PAI-1 response to Ang II is dependent on any hemodynamic stimulation or blood pressure response. In fact, prior in vivo and in vitro research from several groups consistently indicate that pressor infusions lead to increases in t-PA with either no change in PAI-1 or a concomitant decrease in PAI-1.26-29 Thus, the current finding that Ang II infusion leads to an increase in PAI-1 but not t-PA strongly suggests that the mechanism of the observed Ang II effect is not pressor related.
Despite the concordance of our in vivo Ang II data with those observed for Ang TI in vitro,16'17 three potential limitations of the current study must be considered. First, because PAI-1 levels demonstrate a diurnal variation in normal subjects, it theoretically is possible that the time-and dose-related effects we observed occurred independent of Ang II infusion. However, in contrast to the subjects receiving Ang II, the control subjects demonstrated a decline in PAI-1 antigen over time. This finding is consistent with previous research describing the circadian variation of PAI-1, which has demonstrated that levels peak in the early morning hours (when our baseline samples were obtained) and then progressively decrease over the course of the day, a pattern that, if anything, would dilute any true Ang II-induced increase.3031 Second, because infusion of Ang II leads to a reduction in renal plasma flow, it is possible that the increases in PAI-1 we observed with Ang II infusion resulted solely from reduced renal clearance. This explanation for our observed effect is also unlikely as the primary metabolic pathway for PAI-1 is hepatic rather than renal. Moreover, if reduced renal clearance is the sole mechanism leading to increased PAT-1 levels, then t-PA levels would also be expected to increase with Ang II infusion. In the present study, however, levels of t-PA antigen increased in only one of 10 subjects after Ang II infusion. Finally, because increases in glucocorticoid hormone levels have been shown to elevate PAI-1,13 it is possible that an increase in cortisol could contribute to the increase in PAI-1. However, cortisol levels fell in our study during Ang IT infusion, following the usual circadian rhythm.
In summary, these data suggest that infusion of Ang II into normal as well as hypertensive subjects results in a rapid and substantial increase in circulating levels of PAI-1 without a significant change in t-PA. These findings may help to explain clinical observations that suggest a potentially important relation between the renin-angiotensin system and thrombotic risk. Further studies with larger sample sizes will be needed to assess whether a difference exists between normotensive and hypertensive subjects with regard to the PAI-1 response to Ang TI.
